Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

DNA aptamer shows promising mechanism of action
February 2018
SHARING OPTIONS:

IRVING, Texas—This past December saw the 59th American Society of Hematology Annual Meeting & Exposition held in Atlanta, and among the presenters was Caris Life Sciences. The company shared data highlighting a new mechanism of action for treating non-Hodgkin lymphoma (NHL). The data in question demonstrated that the single-stranded DNA aptamer C10.36 specifically binds to heterogeneous nuclear ribonucleoprotein U (hnRNP U), a protein that modulates pre-mRNA splicing. Cancerous cells often display such splicing regulatory factors on their surface, and current beliefs are that disrupted splicing machinery can result in “splicing chaos” that leads to cell death. Caris' study demonstrated in vitro that C10.36 binding to cell-surface hnRNP U led to internalization of the complex, disruption of pre-mRNA splicing and eventually cell death in a subset of NHL cell lines.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.